Lavipharm (ATH:LAVI) EV-to-EBIT : 31.35 (As of Sep. 24, 2024)

Lavipharm EV-to-EBIT Chart

Lavipharm Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-EBIT	Get a 7-Day Free Trial						-	21.38	-	28.58	-

Competitive Comparison of Lavipharm's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lavipharm's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lavipharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lavipharm's EV-to-EBIT falls into.

Lavipharm EV-to-EBIT Calculation

Lavipharm's EV-to-EBIT for today is calculated as:

Lavipharm's current Enterprise Value is €158.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €5.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm  (ATH:LAVI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lavipharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Lavipharm's Enterprise Value for the quarter that ended in Jun. 2024 was €165.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €5.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lavipharm's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lavipharm Business Description